Human SET encodes a nuclear phosphoprotein with a highly acidic carboxyl-terminus, forming a SET-CAN fusion gene in a patient with acute undifferentiated leukemia. SET is highly conserved between species and is ubiquitously expressed, suggesting a widespread biological role. Even though SET is involved in chromatin remodeling and transcriptional activation, its precise role in hematopoietic cells and the contribution of SET-CAN to leukemogenesis remains unknown. We determined the effect of tetracycline-regulatable expression of SET, a deletion mutant of SET, and SET-CAN on the human promonocytic cell line U937T. The expression of SET and SET-CAN inhibited proliferation of these cells. SET accomplishes this through the induction of the differentiation program, an effect that depends on the presence of its acidic domain. SET-CAN most likely inhibits growth by interfering with hCRM1, but it also partially blocks differentiation. Our results are the first demonstration of a potential role of SET in hematopoietic differentiation.
Introduction
Human SET was initially identified as a partner of the SET-CAN fusion gene, which resulted from a translocation or inversion involving chromosome 9q34 in a patient with acute undifferentiated leukemia (AUL). 1 SET-CAN expression is under the control of the SET promoter and it contains almost the entire SET open-reading frame lacking the last six amino acids, fused to the carboxyl-terminal two-third of CAN. 1 CAN is an essential nucleoporin involved in nucleocytoplasmic transport of protein and mRNA. 2 SET and CAN localize mainly to the nucleus and nuclear envelope, respectively, and both are expressed ubiquitously in mouse and human. [2] [3] [4] Mouse, rat 5 and human SET 6 are 94% identical in nucleotide sequence and encode a phosphoprotein containing an acidic C-terminal tail. 3 SET, shows homology to nucleosome assembly proteins (NAPs), which have a role in chromatin remodeling. 7 It has been reported that SET (TAF-Ib) binds to histones in vitro 7 or in vivo as a subunit of the INHAT complex. 8 This complex consists of SET, TAF-Ia, a SET isoform containing a different 24 amino acids long Nterminus and pp32, a putative HLA-associated protein I or I 1 PP2A . The binding of the INHAT complex to histones prevents their acetylation, which causes transcriptional repression. 8 Moreover, the overexpression of SET can inhibit demethylation of DNA, which results in gene silencing. 9 Granzyme A, a serine protease, cleaves SET after Lys 176 , removing its acidic domain, which disrupts its NAP activity. 10 In addition, SET binds and blocks DNase activity of the tumor metastasis suppressor NM23-H1, an activity also negatively regulated by granzyme A cleavage.
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NM23-H1 released of SET inhibition induces apoptosis by causing single-strand DNA nicking in cells. 10 Although there are several additional functions attributed to SET such as the inhibition of protein phosphatase 2A 11, 12 and transcriptional activation, 13 the role of SET in hematopoiesis and the effect of SET-CAN on that function remains elusive. To determine the effect of SET and SET-CAN expression, we used the human promonocytic cell line U937T as a model system and studied the role of these proteins and that of a deletion mutant of SET lacking the acidic tail on the growth and differentiation of this cell line.
Materials and methods

Constructs
Using PCR-based cloning techniques, we removed the Cterminal 51 amino acids of SET (SET Delta Acid, SdelAc), and added a Flag epitope to the N-termini of the open-reading frames of SET (Flag-SET, FS) and SDelAc (FLAG-SdelAc, FSDelAc). We cloned all constructs into the EcoR1 site of the TetVP16-responsive expression vector pUHD10S 2 and their integrity was confirmed by DNA sequencing.
Establishment of inducible cell lines
Stable U937T cell clones, 14 regulatably expressing FS, FSDelAc or SET-CAN (SC) were generated and maintained as described previously. 14 
Immunocytochemistry and Western blot analysis
After 72 h of FS, FSDelAc or SC expression, cells were fixed, permeabilized and stained with primary anti-Flag (1:500; Sigma, St Louis, MO, USA) or affinity-purified polyclonal anti-CAN antibody (1:500; directed against the carboxy-terminus of CAN), and a secondary Alexa 488-conjugated antibody (Molecular Probes, OR, USA). CD11b was detected with anti-CD11b antibody (1:10; Pharmingen, San Diego, CA, USA), followed by incubation with Cy3-conjugated FAB fragment (Jackson ImmunoResearch, PA, USA). FS, FSDelAc and SC protein levels in induced or uninduced cells were determined by separating cell lysates on 8% SDS-PAGE gels, followed by Western blot analysis using primary anti-Flag (1:5000) or rabbit polyclonal anti-SET 3 antibodies (1:4000) and a secondary HRP-conjugated antibody. Equal loading level of the proteins was confirmed by anti-actin antibody (1:1000, Santa Cruz Biotechnology, CA, USA).
Growth curve, apoptosis and cell cycle analysis
To remove tetracycline, cells were washed with RPMI 1640, and plated at a density of 4 Â 10 5 cells/well in six-well plates and cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum in the presence (uninduced) or absence (induced) of tetracycline (three wells/time point). Cells were counted at consecutive days and after propidium iodide (PI) and Annexin V staining, we determined the percentage of dead and apoptotic cells by fluorescence activated cell sorter (FACS). DNA content and cell cycle distribution was analyzed by FACS as described before. 14 
Differentiation assay and FACS analysis
After 16 h of culture of induced and uninduced FS, FSDelAc or SC cells (2.5 Â 10 5 cell/ml), differentiation was stimulated by the addition of vitamin D 3 (10 À7 M in ethanol) or an equivalent amount of ethanol as negative control, and cells were cultured for an additional 48 h (total 64 h of culture). The expression of the CD11b marker was analyzed by FACS after staining with anti-MO1 monoclonal antibody (Beckman-Coulter, Miami, FL). SC cells were also analyzed 24 h after the addition of vitamin D 3 (total 40 h of culture in the presence or absence of tetracycline). The coexpression of CD11b and FS was detected by immunofluorescence, and cell morphology was determined using Giemsa-stained cytospin preparations.
Results
To investigate the effect of SET on the growth and differentiation of the human promonocytic U937T cell line (Boer et al 14 ) , we created tetracycline-inducible clonal lines expressing Flag epitope-tagged SET (FS), or a Flag-tagged deletion mutant of SET lacking the acidic domain (FSDelAc). We determined whether the effects of SET in U937T cells were different from those induced by its oncogenic counterpart SET-CAN, which would ascertain intrinsically different functions of these two proteins. Therefore, we also created tetracycline-inducible clonal U937T lines expressing SET-CAN (SC). The expression of all three proteins without tetracycline was confirmed by immunocytochemistry and Western blot analysis (Figure 1a and  b) . We determined the effect of FS, FSDelAc and SC expression on proliferation and viability of the cells by culturing for 5 days with (uninduced) or without (induced) tetracycline. We counted the cells daily and determined their cell cycle profile, viability and rate of apoptosis by FACS after staining with PI and Annexin V, respectively. Compared to uninduced U937T controls, cells expressing FS and SC, but not FSDelAc showed a 1.6-and 5.9-fold lower proliferation rate after 5 days of induction, respectively (Figure 1c) . The inhibition of proliferation by FS was not caused by an increased rate of death and apoptosis, which remained similarly low to that of uninduced or U937T parental cells (Figure 1d ). In contrast, growth suppression in SCexpressing cells was accompanied by an increasing percentage of cell death and apoptosis amounting to 90% at day 5 of induction ( Figure 1d ). These observations were further supported by flow-cytometric cell cycle analysis of U937T, FS, FSDelAc and SC cells at 5 consecutive days following induction. In agreement with the growth rate, this analysis shows that FSDelAc cells proliferate the same as control U937T cells, whereas FS cells progressively exit the cell cycle and accumulate in G0/G1 phase. By contrast, the surviving SC cells arrest during S phase of the cell cycle (Figure 1e) . U937T parental cells slow down slightly because of the culture becoming confluent.
U937T cells can be induced to differentiate, resulting in cell cycle exit and the expression of the CD11b surface marker. 15 We reasoned that the progressive cell cycle exit of FSoverexpressing cells could be the result of the induction of differentiation. Indeed, by using FACS, we determined that FS induction resulted in a 25-fold upregulation of the CD11b differentiation marker, while the induction of FSDelAc or SC did not have this effect (Figure 2a) . The latter was not caused by an intrinsic inability of the cells to differentiate, because addition for 48 h of the potent stimulator of monocytic differentiation, vitamin D 3 , 15 to uninduced FS, FSDelAc and SC cultures caused 98% of the cells to express CD11b (Figure 2a and c) . As judged by the stable expression of CD11b, the induction of FS or FSDelAc did not affect vitamin D 3 -induced differentiation (Figure 2a-c) , whereas the expression of SC reduced the number of cells expressing CD11b in a dose-dependent manner to 37% after 64 h of SC induction (Figure 2a and d) . As cell death at 64 h after induction measures 60%, we repeated the experiment at 40 h after the induction of SC, 10 h prior to the SC-induced rise in cell death. Also at this time point, SC expression inhibited vitamin D3-induced CD11b expression to 35% (Figure 2e ). This suggests that SC expression inhibits vitamin D 3 -induced differentiation. We also assessed the effect of vitamin D 3 -induced differentiation on the levels of endogenous SET, which increased somewhat during the first 4 h of differentiation ( Figure 2f ) in both ethanol control and vitamin D3-treated cells and then remained stable. We conclude that vitamin D 3 -induced the differentiation of U937T cells is not driven by a large increase in the level of endogenous SET.
Discussion
We have shown that forced expression of SET and SET-CAN inhibits proliferation and induces cell cycle arrest in U937T cells. From our data, we infer that SET induces cell cycle arrest of U937T cells through the induction of differentiation. This activity is dependent on the presence of the acidic tail of SET, which mediates histone and NM23-H1 interaction. 8, 10 In contrast, SET-CAN inhibits differentiation, indicating that fusion of SET to CAN creates a protein with a distinct function. Boer et al 14 have shown that forced expression of DEK-CAN (which possesses the same portion of CAN as SET-CAN) induces cell cycle arrest, due to interference with the leucine-rich nuclear export sequence receptor hCRM1. In fact, the overexpression of CAN or any CAN mutant containing the C-terminal hCRM1 interaction domain exhibits this effect. The cell cycle arrest and enhanced cell death by SET-CAN is also likely to be caused by this interference. However, DEK-CAN did not inhibit the differentiation of U937T cells, 14 suggesting that the suppression of differentiation by SET-CAN might be due to an altered SETrelated rather than a CAN-related function of the fusion protein.
It is important to note that the inhibition of differentiation by SET-CAN is observed well before the SET-CAN-mediated effects of CRM1 inhibition become critical and cause cell death. This may reflect a biologically relevant function of SET-CAN, which was isolated from a patient with AUL. However, unlike the primitive progenitors in which SET-CAN was found, U937T cells are committed myeloid cells. Currently, we are developing a transgenic mouse model expressing SET-CAN to verify whether SET-CAN also inhibits the differentiation of primitive progenitors. As apoptosis in U937T cells caused by SET-CAN and DEK-CAN seems paradoxical for an oncogene it is possible that, similar to MLL-fusion proteins, 16 DEK-CAN and SET-CAN are less well tolerated in U937T cells than in primitive progenitors. In addition, we have indications that SET-CAN in the bone marrow of a SET-CAN AUL patient 1 is expressed at a much lower level than in our SET-CAN U937T cell lines.
As a component of the INHAT complex, SET is involved in inhibiting histone transacetylation resulting in transcription silencing and chromatin compaction. 8, 9 If the effect of SET in U937T cells is mediated via this complex, it is conceivable that SET inhibits the expression of genes stimulating growth, thereby promoting differentiation. Alternatively, SET might inhibit the expression of genes repressing differentiation. In both cases, the upregulation of CD11b would be an indirect effect merely reflecting the fact that the cells differentiate. It is also possible that the upregulation of CD11b is a more direct consequence of SET overexpression, for instance, if SET would inhibit the expression of a repressor of CD11b. We know that significant upregulation of endogenous SET is not involved in vitamin D 3 -induced differentiation of U937T cells, but we believe that overexpression triggers changes in gene expression that in part mimic the effect of vitamin D 3 induction. At present, we have no answer to these questions but we are currently testing the different possibilities.
If indeed SET-CAN inhibits the differentiation of primitive progenitors, its expression could lead to the enlargement of this compartment increasing the likelihood of secondary mutations to occur resulting in leukemia. 17 We hypothesize that as a result of a chromosome translocation, haploinsufficiency of SET in the patient could enhance the differentiation inhibitory effect of 5 cells were stained with Annexin V bound to fluorescein isothiocyanate and 1 mg/ml PI, and analyzed by FACS. (e) The same cells that were used for the growth curve and viability analysis were also further analyzed by FACS to determine the cell cycle profile for each day.
Effects of SET and SET-CAN on human U937
A Kandilci et al SET-CAN and therefore jointly contribute to leukemogenesis. We are currently developing a mouse model to test this hypothesis. Effects of SET and SET-CAN on human U937
